

## In This Issue

1655 In This Issue of *Diabetes Care*

## Presidential Address


1657 2016 Presidential Address: Diabetes at 212°—Confronting the Invisible Disease  
*D. Schatz*

## Clinical Care/Education/Nutrition/Psychosocial Research

→ 1664 Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA<sub>1c</sub>, and Insulin Dose  
*W. Hao, S. Gitelman, L.A. DiMeglio, D. Boulware, and C.J. Greenbaum, for the Type 1 Diabetes TrialNet Study Group*

1671 An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois  
*J.A. Mays, K.L. Jackson, T.A. Derby, J.J. Behrens, S. Goel, M.E. Molitch, A.N. Kho, and A. Wallia*


1677 Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study  
*H. Yamazaki, T. Tsuboya, A. Katanuma, Y. Kodama, S. Tauchi, M. Dohke, and H. Maguchi*

 1684 Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease  
*S.E. Inzucchi, C.M. Viscoli, L.H. Young, K.L. Furie, M. Gorman, A.M. Lovejoy, S. Dagogo-Jack, F. Ismail-Beigi, M.T. Korytkowski, R.E. Pratley, G.G. Schwartz, and W.N. Kernan, for the IRIS Trial Investigators*

→ 1693 Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial  
*B. Ahrén, I.B. Hirsch, T.R. Pieber, C. Mathieu, F. Gómez-Peralta, T.K. Hansen, A. Philotheou, S. Birch, E. Christiansen, T.J. Jensen, and J.B. Buse, for the ADJUNCT TWO Investigators*

1702 Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial  
*C. Mathieu, B. Zinman, J.U. Hemmingsson, V. Woo, P. Colman, E. Christiansen, M. Linder, and B. Bode, for the ADJUNCT ONE Investigators*

1711 Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C)  
*R. Aronson, N. Orzech, C. Ye, R.E. Brown, R. Goldenberg, and V. Brown*

 1718 Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes  
*S. Hadjadj, J. Rosenstock, T. Meinicke, H.J. Woerle, and U.C. Broedl*

→ 1729 Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease  
*G. Ruiz-Hurtado, L.M. Ruilope, A. de la Sierra, P. Sarafidis, J.J. de la Cruz, M. Gorostidi, J. Segura, E. Vinyoles, and J.R. Banegas*

## Epidemiology/Health Services Research


1738 Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?  
*A. Fouts, L. Pyle, L. Yu, D. Miao, A. Michels, J. Krischer, J. Sosenko, P. Gottlieb, A.K. Steck, and the Type 1 Diabetes TrialNet Study Group*

1745 Longitudinal Associations of Exposure to Perfluoroalkylated Substances in Childhood and Adolescence and Indicators of Adiposity and Glucose Metabolism 6 and 12 Years Later: The European Youth Heart Study  
*S.L. Domazet, A. Grøntved, A.G. Timmermann, F. Nielsen, and T.K. Jensen*

1752 Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease  
*M. Liang, J.W. McEvoy, Y. Chen, A.R. Sharrett, and E. Selvin*

→ 1760 The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial  
*M.B. Weber, H. Ranjani, L.R. Stamez, R.M. Anjana, M.K. Ali, K.M.V. Narayan, and V. Mohan*

## Emerging Technologies and Therapeutics

 1768 Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial  
*C.H. Wysham, L. MacConell, and E. Hardy*

1777 Efficacy and Safety of Cannabidiol and Tetrahydrocannabinavir on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study  
*K.A. Jadoon, S.H. Ratcliffe, D.A. Barrett, E.L. Thomas, C. Stott, J.D. Bell, S.E. O'Sullivan, and G.D. Tan*

## Pathophysiology/Complications

1787 Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study  
*K.F. Hunt, J.T. Dunn, C.W. le Roux, L.J. Reed, P.K. Marsden, A.G. Patel, and S.A. Amiel*

1796 Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes  
*K. Mohammedi, M. Woodward, Y. Hirakawa, S. Zoungas, B. Williams, L. Lisheng, A. Rodgers, G. Mancina, B. Neal, S. Harrap, M. Marre, and J. Chalmers, on behalf of the ADVANCE Collaborative Group*

1804 Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects  
*R. Eldor, G. Daniele, C. Huerta, M. Al-Atrash, J. Adams, R. DeFronzo, T. Duong, J. Lancaster, M. Zirie, A. Jayyousi, and M. Abdul-Ghani*

## Cardiovascular and Metabolic Risk

1811 A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies  
*N. Simons, J.M. Dekker, M.M.J. van Greevenbroek, G. Nijpels, L.M. 't Hart, C.J.H. van der Kallen, C.G. Schalkwijk, N.C. Schaper, C.D.A. Stehouwer, and M.C.G.J. Brouwers*

1818 Intensive Glycemic Therapy in Patients With Type 2 Diabetes on  $\beta$ -Blockers  
*T. Tsujimoto, T. Sugiyama, M. Noda, and H. Kajio*

## Novel Communications in Diabetes

1827 Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With Type 1 Diabetes  
*A.C. Wotherspoon, I.S. Young, D.R. McCance, C.C. Patterson, M.J.A. Maresh, D.W.M. Pearson, J.D. Walker, and V.A. Holmes, for the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group*

Keep up with the latest information for *Diabetes Care* and other ADA titles via Facebook (/ADAJournals) and Twitter (@ADA\_Journals).

All articles in *Diabetes Care* are available online at [diabetes.org/diabetescare](http://diabetes.org/diabetescare). Cover articles (➡) and select content are available free of charge. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

ADA's Diabetes Core Update podcast is available at [diabetesjournals.org](http://diabetesjournals.org) and through iTunes.

Icons shown below appear on the first page of an article if more information is available online.



Free Article



Video



Podcast



Supplementary Data



Companion Article

## Review

- 1830** Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities  
*G. Musso, M. Cassader, S. Cohny, F. De Michieli, S. Pinach, F. Saba, and R. Gambino*

## Erratum

- 1846** Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes  
*J.M. Gaziano, A.H. Cincotta, C.M. O'Connor, M. Ezrokhi, D. Ruttly, Z.J. Ma, and R.E. Scranton*

## Issues and Events

- 1847** Issues and Events

## e-Letters – Observations

- e163** Effect of Regular Exercise Commenced in Early Pregnancy on the Incidence of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Randomized Controlled Trial  
*C. Wang, Y. Wei, X. Zhang, Y. Zhang, Q. Xu, S. Su, L. Zhang, C. Liu, Y. Feng, C. Shou, K.J. Guelfi, J.P. Newnham, and H. Yang*
- e165** A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy  
*P.D. Farjo, K.M. Kidd, and J.L. Reece*
- e167** Subjects With Extreme-Duration Type 1 Diabetes Exhibit No Structural or Functional Abnormality on Cardiac MRI  
*O. Asghar, C. Miller, S. Ray, M. Schmitt, and R.A. Malik*
- e169** Impact of the Gather mHealth System on A1C: Primary Results of a Multisite Randomized Clinical Trial Among People With Type 2 Diabetes in India  
*N.J. Kleinman, A. Shah, S. Shah, S. Phatak, and V. Viswanathan*
- e171** hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study  
*D. Zahn, S. Herpertz, C. Albus, N. Hermanns, C. Hiemke, W. Hiller, K. Kronfeld, J. Kruse, B. Kulzer, M.J. Müller, C. Ruckes, and F. Petrar*
- e174** A Smartphone Application to Deliver a Treat-to-Target Insulin Titration Algorithm in Insulin-Naive Patients With Type 2 Diabetes: A Pilot Randomized Controlled Trial  
*Y.M. Bee, A.P.M. Batcagan-Abueg, C.-L. Chei, Y.K. Do, B. Haaland, S.-Y. Goh, P.C. Lee, P.P.S. Chiam, E.T.L. Ho, and D.B. Matchar*
- e177** International Comparison of Smoking and Metabolic Control in Patients With Type 1 Diabetes  
*S.E. Hofer, K. Miller, J.M. Hermann, D.J. DeSalvo, M. Riedel, I.B. Hirsch, W. Karges, R.W. Beck, R.W. Holl, and D.M. Maahs, for the DPV Initiative and the T1D Exchange Clinic Network*
- e179** Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity  
*J. Hu, S. Yang, A. Zhang, P. Yang, X. Cao, X. Li, R. Goswami, Y. Wang, T. Luo, K. Liao, Q. Cheng, X. Xiao, and Q. Li*

## e-Letters – Comments and Responses

- e181** Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. *Diabetes Care* 2016;39:653–663  
*G. Reaven*

- e182** Response to Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. *Diabetes Care* 2016;39:653–663  
*K.M.V. Narayan*

- e183** Comment on Almurthi et al. Reduced Lower-Limb Muscle Strength and Volume in Patients With Type 2 Diabetes in Relation to Neuropathy, Intramuscular Fat, and Vitamin D Levels. *Diabetes Care* 2016;39:441–447  
*G. Treiber, L. Baillet-Blanco, M. Hugo, E. Pupier, I. Redonnet-Vernhet, S. Cambos, and V. Rigalleau*

- e184** Response to Comment on Almurthi et al. Reduced Lower-Limb Muscle Strength and Volume in Patients With Type 2 Diabetes in Relation to Neuropathy, Intramuscular Fat, and Vitamin D Levels. *Diabetes Care* 2016;39:441–447  
*M.M. Almurthi, N.D. Reeves, F.L. Bowling, A.J.M. Boulton, M. Jeziorska, and R.A. Malik*

- e186** Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. *Diabetes Care* 2016;39:973–981  
*L. Monnier, C. Colette, and D.R. Owens*

- e188** Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. *Diabetes Care* 2016;39:973–981  
*K.D. O'Brien, I.B. Hirsch, M.C. Riddle, and J.L. Probstfeld, for the FLAT-SUGAR Trial Investigators*

- e189** Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes Care* 2016;39:1424–1430  
*Z. Aryan, S. Noshad, M. Afarideh, and A. Esteghamati*

- e190** Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes Care* 2016;39:1424–1430  
*S. Sharif, Y. van der Graaf, H.M. Nathoe, H.W. de Valk, F.L.J. Visseren, and J. Westerink, on behalf of the SMART Study Group*

- e192** Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. *Diabetes Care* 2016;39:264–270  
*A.J. Munoz, S. Girish, and M.B. Winder*

- e193** Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. *Diabetes Care* 2016;39:264–270  
*M.R. Rickels, K.J. Ruedy, N.C. Foster, C.A. Piché, H. Dulude, J.L. Sherr, W.V. Tamborlane, K.E. Bethin, L.A. DiMeglio, R.P. Wadwa, A.J. Ahmann, M.J. Haller, B.M. Nathan, S.M. Marcovina, E. Rampakakis, L. Meng, and R.W. Beck, for the T1D Exchange Intranasal Glucagon Investigators*